Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ICARIIN CRS (25 MG)

ICARIIN CRS (25 MG)

ND

DISCOVER
EPIMEDIUM LEAF FOR SYSTEM SUITABILITY HRS (520 MG)

EPIMEDIUM LEAF FOR SYSTEM SUITABILITY HRS (520 MG)

ND

DISCOVER
PALONOSETRON IMPURITY A CRS (0.002 MG)

PALONOSETRON IMPURITY A CRS (0.002 MG)

ND

DISCOVER
PALONOSETRON IMPURITY MIXTURECRS (0.002 MG)

PALONOSETRON IMPURITY MIXTURECRS (0.002 MG)

ND

DISCOVER
PROCAINE HYDROCHLORIDE FOR IDAND ASSAY CRS (120 MG)

PROCAINE HYDROCHLORIDE FOR IDAND ASSAY CRS (120 MG)

ND

DISCOVER
CARBOPROST FOR SYSTEM SUITABILITY CRS (5 MG)

CARBOPROST FOR SYSTEM SUITABILITY CRS (5 MG)

ND

DISCOVER
HYDROXYZINE IMPURITY E CRS (15 MG)

HYDROXYZINE IMPURITY E CRS (15 MG)

ND

DISCOVER
HYDROXYZINE FOR SYSTEM SUITABILITY CRS (0.6 MG)

HYDROXYZINE FOR SYSTEM SUITABILITY CRS (0.6 MG)

ND

DISCOVER
POLYSILOXANE D4 CRS (50 MG)

POLYSILOXANE D4 CRS (50 MG)

ND

DISCOVER
POLYSILOXANE D5 CRS (50 MG)

POLYSILOXANE D5 CRS (50 MG)

ND

DISCOVER
POLYSILOXANE D6 CRS (50 MG)

POLYSILOXANE D6 CRS (50 MG)

ND

DISCOVER
FLUTICASONE PROPIONATE FOR SYSTEM SUITABILITY A CRS (0.2 MG)

FLUTICASONE PROPIONATE FOR SYSTEM SUITABILITY A CRS (0.2 MG)

ND

DISCOVER